High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia.
High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia.
复制标题
DOI：
10.4081/hr.2010.e3
复制
发表时间：
2010-01-26
影响因子：
0.9
通讯作者：
Kreuzer KA
中科院分区：
文献类型：
--
作者：
Erdfelder F;Hertweck M;Filipovich A;Uhrmacher S;Kreuzer KA
我们测定了112例慢性淋巴细胞白血病（CLL）样本中淋巴增强子结合因子-1（LEF 1）mRNA的表达，并评估了与预后标志物ZAP 70和CD 38、Binet分期、外周血淋巴细胞百分比和纤调蛋白（FMOD）转录本的相关性。在ZAP 70阳性和ZAP 70阴性患者中，平均LEF 1相对表达比率（RER）分别为53.72和37.10（P=0.004）。然而，我们没有观察到CD 38阳性和CD 38阴性患者之间LEF 1表达的显著差异。此外，需要治疗的患者显示平均LEF 1 RER为85.61，而最近诊断为Binet A期的患者平均仅为22.01（P<0.001）。我们还发现LEF 1与淋巴细胞百分比和FMOD表达显著相关。我们的研究结果表明，LEF 1高表达与不良预后和疾病进展相关。因此，LEF 1可能参与疾病进展过程，并可能作为CLL风险评估和/或监测的分子参数。
We determined lymphoid enhancer-binding factor-1 (LEF1) mRNA expression in 112 chronic lymphocytic leukemia (CLL) samples and assessed correlations with the prognostic markers ZAP70 and CD38, Binet stages, the percentage of lymphocytes in the peripheral blood, and fibromodulin (FMOD) transcripts. The mean LEF1 relative expression ratios (RER) were 53.72 and 37.10 in ZAP70-positive and ZAP70-negative patients, respectively (P=0.004). However, we did not observe a significant difference in LEF1 expression between CD38-positive and CD38-negative patients. Moreover, patients requiring treatment showed a mean LEF1 RER of 85.61 whereas patients in recently diagnosed Binet A stage had a mean of only 22.01 (P<0.001). We also found significant correlations of LEF1 with the percentage of lymphocytes and FMOD expression. Our results suggest that high LEF1 expression is associated with poor prognosis and disease progression. Thus, LEF1 might be involved in the process of disease progression and possibly can serve as a molecular parameter for risk assessment and/or monitoring of CLL.